You just read:

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China

News provided by

Ascentage Pharma

Apr 07, 2020, 07:00 ET